Solasia initiates darinaparsin injection Phase I trial in Japan

The clinical trial is designed to assess the safety and tolerability of darinaparsin injection for the treatment of peripheral T-cell lymphoma (PTCL).

Darinaparsin is a mitochondrial-targeted agent being developed to treat various hematologic and solid cancers.

Solasia said several clinical trials showed that darinaparsin injection has good tolerability and safety.

The comapany said it has gained license from Ziopharm Oncology to develop and market darinaparsin, in both intravenous and oral forms in some of the states in Asia.

It has also partnered with Acronet to work closely together on the Phase I study of darinaparsin in Japan.